Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GSK726701A is a new type of prostaglandin E2 receptor 4 (EP4) partial agonist (pEC50: 7.4).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 8-10 weeks | $ 1,820.00 | |
50 mg | 8-10 weeks | $ 2,380.00 | |
100 mg | 8-10 weeks | $ 3,100.00 |
Description | GSK726701A is a new type of prostaglandin E2 receptor 4 (EP4) partial agonist (pEC50: 7.4). |
In vitro | GSK726701A has high selectivity (>100-fold) against a set of other prostaglandin receptors (EP1-3 , DP1 , FP, IP, TP) and no significant activity against a wider panel of targets. |
In vivo | GSK726701A exhibits robust efficacy in various animal models for both inflammatory and neuropathic pain. Demonstrating time-dependent, complete reversal of CCI-induced mechanical allodynia at a dosage of 3mg/kg, GSK726701A matches the efficacy of the clinically acclaimed gabapentin, administered at 30mg/kg. Additionally, GSK726701A possesses an ED50 value of 0.2mg/kg in the FCA acute rat model of inflammatory pain, and showcases favorable pharmacokinetics across rat, dog, and monkey studies. |
Molecular Weight | 423.43 |
Formula | C24H22FNO5 |
CAS No. | 945721-87-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GSK726701A 945721-87-9 Others GSK-726701A inhibitor inhibit